Investors

Cellics is a pre-clinical biotech company that uses the innovative Nanosponge Technology for a rich product pipeline including infectious diseases, rare and ultra-rare diseases, anti-venom applications, and vaccines. The Nanosponge Technology can also be used for targeted delivery. Cellics has completed Round A financing and will soon start Round B financing.

If you are interested in investing Cellics Therapeutics, please contact us.